Advice
Following an abbreviated submission
cladribine (Litak) is accepted for use in NHS Scotland for the treatment of hairy cell leukaemia.
In patients for whom cladribine is an appropriate agent for this indication, the 2mg/ml solution allows administration by subcutaneous bolus injection over five consecutive days rather than by continuous intravenous infusion of the existing 1mg/ml solution for seven consecutive days. This may confer advantages in terms of convenience to patients and service delivery at a lower cost per course.
Download detailed advice65KB (PDF)
Medicine details
- Medicine name:
- cladribine (LITAK)
- SMC ID:
- 537/09
- Indication:
- Treatment of hairy cell leukaemia.
- Pharmaceutical company
- LIPOMED GmbH
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 March 2009